Calidi Biotherapeutics (CLDI) revenue and earnings history
Calidi Biotherapeutics's annual figures for 4 fiscal years, as filed with the SEC.
Revenue and net income, 4 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$20.2M | −$19.9M | −$21.3M | — | — | $2.11M | — | — | $5.82M | $600K | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Calidi Biotherapeutics (CLDI) on OQRO.
Common questions
Has Calidi Biotherapeutics been profitable?
It reported a net loss in 4 of the years shown (2022, 2023, 2024, 2025). The highest net income was −$19.9M in fiscal 2025.
Why is earnings per share not in this table?
Each year's figure here comes from the newest annual report that states it. After a stock split, earlier reports and later reports state per-share figures on different share counts, so a column of EPS would mix the two. Net income is not affected by splits.
Where these figures come from
The SEC’s companyfacts data: every figure Calidi Biotherapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
